Hyaluronidase: using it in an occlusion, and when not to

Hyaluronic acid is the default facial filler largely because a mistake can be undone with hyaluronidase. That safety net only works if you can use the enzyme decisively when it is needed. By then it is too late to read a protocol for the first time.

Being ready means four things. You know that correcting a cosmetic result and treating an occlusion are different interventions. You recognise an occlusion early. You flood the whole affected territory and repeat until blood flow returns. And your clinic can manage anaphylaxis and has an agreed route to ophthalmology.

Cosmetic correction and occlusion are different interventions

The commonest error is treating hyaluronidase as one intervention with one dose. An overfilled tear trough and a vascular occlusion differ in the amount of enzyme, the speed of response and the point at which treatment ends.

Cosmetic correction covers a nodule, a Tyndall effect under thin skin, an asymmetry or a migration that will not settle. There is no time pressure. Use small amounts, place them precisely and reassess after two weeks. The enzyme also breaks down the patient's own hyaluronic acid, and overshooting leaves a hollow that takes months to recover.

Vascular occlusion means filler has entered or compressed a vessel and tissue is losing its blood supply. The amount is high, the whole area is flooded, and treatment repeats until perfusion returns. Hesitation costs tissue.

Unexplained colour change on one side is an occlusion until proven otherwise

The classic picture is immediate, disproportionate pain and blanching along a vascular territory. Within hours comes a dusky, net-like mottling that does not blanch under pressure, with slow capillary refill. In practice pain may be modest, especially after generous local anaesthesia, and early skin change can be mistaken for ordinary post-injection redness [2].

So treat asymmetry as the alarm. Colour change confined to one vascular territory, on one side, that does not match the other side after an identical injection, is an occlusion until proven otherwise. Waiting for certainty is how a recoverable event becomes necrosis.

In an occlusion, flood the territory and keep repeating

The amounts depend on the preparation licensed in your country and belong in your clinic's written protocol, agreed with your medical lead and checked against current guidance. The principles:

  • Treat the whole ischaemic territory, not the injection point. The filler may sit in the vessel well beyond where the needle went.
  • Expect to use far more than for any cosmetic correction. Instincts from dissolving a nodule are on the wrong scale, so take the amount from the protocol, not from memory.
  • Repeat at intervals until capillary refill, colour and pain return to normal. Partial improvement is a reason for the next round, not for stopping.
  • Inject into the ischaemic tissue, not into the artery. The enzyme spreads well through tissue planes, which is why flooding works [3]. Intra-arterial hyaluronidase is described only as a second-line option for specialists [2], not a first step in an aesthetic clinic.

Adjuncts vary. Current guidance lists warmth and massage alongside the enzyme, and several protocols add aspirin by extrapolation from other ischaemic conditions. Topical nitroglycerin paste appears in consensus guidance as an option [2][3], but its benefit is unproven. None of these replaces adequate, repeated hyaluronidase, and none should delay it.

Any visual symptom is a different emergency. Refer to ophthalmology immediately, at the same time as starting the occlusion protocol: minutes count, most published cases of vision loss after filler did not recover, and it is not managed from an aesthetic clinic [1].

In an emergency, treat without waiting for an allergy test

Hyaluronidase comes from animal or recombinant sources. Hypersensitivity is uncommon but real, from local swelling and redness to anaphylaxis. The intradermal test dose is contested: it delays treatment, and a negative test does not rule out a reaction to a much larger dose given later.

Many emergency protocols advise against delaying treatment for a skin test in a genuine occlusion: you treat, with resuscitation equipment and adrenaline within reach. In elective correction nothing is time-critical, so testing is reasonable and costs only a delay. Either way, consensus guidance warns that the enzyme can cause allergic reactions, and a clinic must be able to manage anaphylaxis before it stocks the enzyme at all [3].

Three situations where dissolving first is the wrong call

The filler is not hyaluronic acid. Hyaluronidase does nothing to poly-L-lactic acid, calcium hydroxylapatite, polymethylmethacrylate or silicone, so it only adds a second intervention. Your notes should record what was injected, when and where, including treatment done elsewhere.

The patient is unhappy but the result is not wrong. Dissolving on request in the first days, before swelling settles, often leads to a worse outcome. Most early dissatisfaction is oedema, and two weeks of reassurance is a legitimate treatment.

A late nodule that is tender and warm. It may be an infection or a delayed inflammatory reaction rather than a placement problem. Consensus guidance treats suspected infection with antibiotics first and gives hyaluronidase only alongside them, so that infected material is not spread [3].

A ready clinic has more than a vial

Keep the enzyme in date and in the room where you inject. Have a written plan you never have to search for, anaphylaxis equipment and staff trained to use it, a colleague or referral route reachable by phone, and an agreed ophthalmology pathway.

The technique that gives a good result and the one that causes an occlusion are the same; the difference is what happens in the twenty minutes afterwards. When you choose training, look for one where you rehearse those minutes under supervision, not only the placement.

Read next

Hands-on courses on this topic

Browse hands-on courses

Training Blog